Oligomerix: Funding, Investors & Team (Oct 2026)
Oligomerix is a biopharmaceutical company founded in 2006 by co-founders Eliot J. Davidowitz and James Moe. The Company is exploiting its novel research that allows rapid generation of stable amyloid oligomers as targets for drug discovery. These systems will enable target identification and validation, and drug discovery for Alzheimer's and other neurodegenerative diseases.
Oligomerix has raised $8.0M across 3 funding rounds on record, the most recent an undisclosed round of $1.9M announced in Jun 2026.
That round is below the $8.1M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Oligomerix Company Profile and Key Stats
Latest funding round on record: Jun 2026.
Oligomerix Funding Rounds
Oligomerix raised $2.7M in a Series B announced in Jun 2022.
2 months later, a Grant of $3.4M was announced in Aug 2022.
3.8 years later, an undisclosed round of $1.9M was announced in Jun 2026.
Oligomerix Founders and Leadership Team
No contact details are on record for this team yet.
Oligomerix Funding Compared to Other Biotechnology Startups
Oligomerix's latest round of $1.9M is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Oligomerix in Biotechnology and Bronx
Companies Similar to Oligomerix
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…
Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.
Serán is a contract development and manufacturing organization providing a comprehensive suite of…
Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from…
Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from…
Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat…
Circle Pharma is a biotechnology company in the initial stages of development that uses unique computational…
Evvy is for people with vaginas who want to be empowered with information about their microbiome. Their…
Oligomerix Funding FAQs
What does Oligomerix do?
Oligomerix is a biopharmaceutical company founded in 2006 by co-founders Eliot J. Davidowitz and James Moe. The Company is exploiting its novel research that allows rapid generation of stable amyloid oligomers as targets for drug discovery. These systems will enable target identification and validation, and drug discovery for Alzheimer's and other neurodegenerative diseases.
How much funding has Oligomerix raised?
Oligomerix has raised $8.0M across 3 rounds on record. The most recent is an undisclosed round of $1.9M announced in Jun 2026.
When did Oligomerix last raise funding?
Oligomerix's most recent funding round on record is an undisclosed round of $1.9M, announced in Jun 2026.
Who founded Oligomerix?
FundedIQ lists Bob Foerster (Founder), Eliot Davidowitz (Founder) at Oligomerix.
Who is the CEO of Oligomerix?
James Moe is listed as CEO at Oligomerix.
Where is Oligomerix headquartered?
Oligomerix is based in Bronx, New York, United States.
How many employees does Oligomerix have?
Oligomerix is in the 11-50 employee band.
How does Oligomerix's funding compare to other Biotechnology startups?
Oligomerix's latest round of $1.9M is below the $8.1M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's Oligomerix Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Oligomerix is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.